Miscellaneous Flashcards
1
Q
Expiration of rejuvenated RBCs in CPD, CPDA-1
A
10 years
2
Q
Expiration of rejuvenated RBCs in AS-1
A
3 years
3
Q
Risk of D sensitization after D+ PLT
A
~4%
4
Q
Preservative for frozen PLT
A
DSMO
5
Q
PF24RT24 can only be made from …
A
apheresis PLT
6
Q
Liquid plasma storage temperature and expiration
A
1-6C/5 days after whole blood expiration date
7
Q
Amount of vWF in unit of cryo
A
80-120 IU
8
Q
Amount of FXIII in unit of cryo
A
40-60 IU
9
Q
Albumin and plasma protein fraction composition
A
Albumin: 96% albumin, 4% Igs
PPF: 83% albumin, 17% Igs
10
Q
DDAVP dose
A
0.3-0.4 ug/kg
11
Q
cryo dose fo vWD
A
1 unit/10 kg Q 8 hrs
12
Q
sensitivity of visible hemolysis
A
> 2.5-5 ml of hemolysis
13
Q
AHTR incidence
A
1/76,000
14
Q
Fatal AHTR incidence
A
1/1.8 million
15
Q
PLT contamination rate
A
1/3000
16
Q
TRALI incidence
A
1/1200 - 190,000
17
Q
Anaphylactic reaction incidence
A
1/20,000-50,000
18
Q
Epi dose
A
0.2-0.5 ml of 1:1000 epi (IM/SQ)
19
Q
pan-positive reactions and auto control at IS/37C but negative at IAT
A
Antibody to reagent
20
Q
Normovolemic hemodilution storage of blood at RT and 1-6C
A
8 hours and 24 hours
21
Q
Drug with highest date rate in AIHA
A
Fludarabine
22
Q
Average RBC engraftment
A
20 days
23
Q
Average Neutrophil engraftment
A
14 days
24
Q
Average platelet engraftment
A
19 days
25
Aedes vector
Chikungunya
26
Anaopheles vector
Malaria
27
Ixodes scapularis
Babesia, Lyme disease
28
Black (Silum) fly
Onchocerca
29
Triatomine
Chagas
30
Bee venom - Apitoxin (melittin)
can lead to hemolysis via phospholipase A2
31
1 PBV removes
63% of plasma substance
32
1.5 PBV removes
78% of plasma substance
33
2 PBV removes
85% of plasma substance
34
2.5 PBV removes
92% of plasma substance
35
3 PBV removes
95% of plasma substance
36
PTP a/w with HLA
DRB3*01:01 (DR52)
37
Cappelini Effect
weak D expression when Ce in trans
38
Cobalt 60 verification
Q 6 months
39
Cesium 137 verification
Annually
40
RBC should be frozen within ___
6 days unless rare unit
41
Mean hgb in apheresis RBC
>60 g/dL with 95% > 50 g/dL
42
Mean hgb in leukoreduced apheresis RBC
>51 g/dL with 95% > 42.5 g/dL
43
MKMK phenotype
M-N-S-s-U-
44
En(a) phenotype
M-N-
45
GPB closely a/w with ...
RhD
46
Go(a) a/w this partial D type
DIV
47
These weak Ds can make allo-anti-D
4.2 and 15
48
Matuhasi Ogata phenomenon
Nonspecific uptake of IgG by RBCs when another antibody is coating the cells (often seen in eluate)
49
Hubener Thomsen Friedenreich phenomenon
"cryptic" antigen uncovered causing polyagglutination (e.g. T antigen)
50
Knull individuals can produce anti-____
Ku
51
FVII padua have prolonged PTT with _____ thromboplastin
rabbit (normal with bovine)
52
Incidence of bruising and hematoma during donation
9-16%
53
Incidence of vasovagal reaction during donation
2-5%
54
Incidence of nerve injury during donation
0.002%
55
Normovolemic Hemodolution crystalloid and colloid to blood ratios
3ml:1ml and 1ml:1ml
56
Cell saver vaccum setting
150 Torr
57
B3 phenotype
Taiwan (mf on forward typing)
58
Acquired B phenotype associated with these bacteria (2)
1. Proteus vulgaris
| 2. E. coli
59
TH-1
binds only A1 cells (like Dilochos Biflorus)
60
of D antigens in weak D
200-5,000
61
1st CXM
1907 Ottenberg
62
1st animal to human transfusion
1667 Jean Baptiste Denis
63
1st human to human transfusion
1818 James Blundell
64
% of directed donor units used
70%
65
Donor testing for therapeutic T cells
7 days before or after collection
66
Donor testing for HPC and oocytes
30 days before up to 7 days after collection
67
HLA platelet matching: A
4 antigens matched
68
HLA platelet matching: BIU
3 antigens matched, one untested (homozygous)
69
HLA platelet matching: BIX
3 antigens matched, one in same crossreactive group
70
HLA platelet matching: B2U
2 antigens matched, 2 unknown (homozygous)
71
HLA platelet matching: B2UX
2 antigens matched, 1 unknown (homozygous), one in same crossreactive group
72
HLA platelet matching: B2X
2 antigens matched, 2 in same crossreactive groups
73
C
1 antigens mismatched
74
D
2 antigens mismatched
75
Granulocyte lifespan - native and with G-CSF stimulation
8 hrs and 24 hrs
76
Contraindication to 8-MOP
Aphakia (absense of lenses)
77
Freq of DHTR
1/2000-5000
78
Freq of DSTR
1/3000
79
Culex pipens vector
WNV
80
Normal D antigen
10,000 - 3,000
81
Lu null
poikilocytosis
82
Duffy
chemokine receptor
83
Knoops
C3b/C4b, CR1 receptor
84
Indian
lymphocyte homing receptor/hyaloronan receptor/CD44 adhesion, polio
85
Kidd
urea transporter
86
Colton
water transporter (auaporin)
87
Diego/Wright
Band 3 ion exchange
88
Chido/Rodger
(C4B/C4A)
89
Cromer
Decay acceleratin factor (DAF) CD55/E. coli, coxsackie, echovirus
90
Gerbich
Glycophorin C&D
91
Duffy, Cad, MNS
Plasmodium
92
Anton (AnWj)
H. influenzae
93
In-vitro hemolysis in antibody testing
I, A, B, Le(a/b), JK(a/b), p, pPk, Vel
94
Brendemon phenomen
transient Le(a-b-) phenotype during pregnancy and development of anti-Le antibody
95
Color of AHG reagent
Green
96
Color of Anti-d reagent
Gray
97
P1 phenotype antigens
P1,P,Pk
98
P1 phenotype antibodies
None
99
P2 phenotype antigens
P,Pk
100
P2 phenotype antibodies
anti-P1
101
Pk phenotype antigens
Pk
102
Pk phenotype antibodies
anti-P
103
p phenotype antigens
None
104
p phenotype antibodies
anti-P1,P,Pk
105
Allowable plasma loss in one year for 100-175 lb donor
12 L
106
Allowable plasma loss in one year for >175 lb donor
14.4 L
107
Frequent plasmapheresis donor - required serum protein
> 6.0 g/dL
108
Post-deglyceralization RBC recovery
>80%
109
Post-leukoreduction RBC recovery
>85%
110
Expiration of deglyceralized cells in closed system
14 days at 1-6C
111
Leukoreduction of 5 x 10^6 helps to prevent
CMV transmission and HLA immunization
112
Leukoreduction of 5 x 10^8 helps to prevent
FNHTR
113
Percentage of wasted autologous units
30%
114
CPDA rejuvenation
w/in 6 days of expiration or 3 days after expiration in a closed system
